Biogen narrows its Aduhelm label after FDA left the floodgates open
While the FDA had controversially approved Biogen’s new Alzheimer’s drug Aduhelm with a wide label for anyone with the debilitating disease, Biogen announced Thursday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
